0
Abstract Views
0
PDF Download
Case-Study

Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis Associated with Paracetamol in a Patient with Diabetes Mellitus

Nidya Tri Fitria Febriola University of Surabaya, Indonesia Correspondence ffebriola@gmail.com
,
Binti Muzayyanah Dr Iskak Regional Public Hospital, Indonesia Correspondence ffebriola@gmail.com
,
Sekar Puspita Lilasari Dr Iskak Regional Public Hospital, Indonesia Correspondence ffebriola@gmail.com
,
Jainuri Erik Pratama Dr. Kariadi Central General Hospital, Indonesia Correspondence erik.rssa@gmail.com
,
Antonius Adji Prayitno Setiadi University of Surabaya, Indonesia Correspondence adji_ps@staff.ubaya.ac.id
,
Fauna Herawati University of Surabaya, Indonesia Correspondence fauna@staff.ubaya.ac.id
,
Marisca Evalina Gondokesumo University of Surabaya, Indonesia Correspondence marisca@staff.ubaya.ac.id
Pages 87-95
Browse this journal

Abstract

Paracetamol is an over-the-counter medication widely used for the management of fever and pain, resulting in a continuous increase in its consumption. Although generally considered safe and well tolerated, paracetamol may, in rare cases, cause severe and life-threatening adverse reactions, including Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). SJS/TEN is a severe drug reaction associated with high morbidity and mortality. We report a case of paracetamol-induced SJS/TEN in a patient with diabetes mellitus. The diagnosis was established based on clinical manifestations and a history of drug exposure. The patient was managed with supportive and pharmacological therapy under close monitoring, including careful glycemic control. This case report highlights the importance of vigilance for severe adverse drug reactions, even when commonly perceived safe medications are used.

There is no Figure or data content available for this article

References

  • 1. Freo U, Ruocco C, Valerio A, Scagnol I, Nisoli E. Paracetamol: A review of guideline recommendations. J Clin Med. 2021;10(15). doi:10.3390/jcm10153420
  • 2. Ayoub SS. Paracetamol (acetaminophen): A familiar drug with an unexplained mechanism of action. Temperature. 2021;8(4):351-371. doi:10.1080/23328940.2021.1886392
  • 3. Bebenista MJ, Nowak JZ. Paracetamol: Mechanism Of Action, Applications And Safety Concern. Acta Poloniae Pharmaceutica-Drug Research. 2014;71(1):11-23.
  • 4. Moriarty C, Carroll W. Paracetamol: Pharmacology, prescribing and controversies. Arch Dis Child Educ Pract Ed. 2016;101(6):331-334. doi:10.1136/archdischild-2014-307287
  • 5. Royal Pharmaceutical Society. British National Formulary 83. 83rd ed. BMJ Group; 2022. www.sps.nhs.uk/ukdilas
  • 6. Gerriets V, Anderson J, Patel P, Nappe TM. Acetaminophen. National Library of Medicine. Published January 11, 2024. https://www.ncbi.nlm.nih.gov/books/NBK482369/?report=printable. Accessed June 2, 2024
  • 7. Wahyu Rahmawati Y, Mira Indramaya D. Studi Retrospektif: Sindrom Stevens-Johnson Dan Nekrolisis Epidermal Toksik (A Retrospective Study: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis).
  • 8. Abulatan IT, Ben-David SG, Morales-Colon LA, Beason E, Fakoya AO. A Compilation of Drug Etiologies of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Cureus. Published online November 13, 2023. doi:10.7759/cureus.48728
  • 9. Yulisa D, Menaldi L. Tata Laksana Terintegrasi Sindrom Stevens-Johnson (SJS) dan Nekrolisis Epidermal Toksik (NET). CDK-321. 2023;50(10):549-553.
  • 10. Diana R, Irwanto ME. Patofisiologi Dan Manajemen Terapi Sindrom Stevens-Johnson (Ssj) Dan Nekrolisis Epidermal Toksik (NET). Medicinus. 2020;33(2):50-62.
  • 11. Milosavljević MN, Pejčić A V., Milosavljević JZ. A review of published cases of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with the use of acetaminophen. Cutan Ocul Toxicol. 2021;40(3):280-292. doi:10.1080/15569527.2021.1942896
  • 12. Creamer D, Walsh SA, Dziewulski P, Exton LS, Lee HY, Dart JKG, et al. U.K. guidelines for the management of Stevens–Johnson syndrome/toxic epidermal necrolysis in adults 2016. British Journal of Dermatology. 2016;174(6):1194-1227. doi:10.1111/bjd.14530
  • 13. Putri OE, Oktavriana T, Octarica SG, Lauda Anandita B, Pradestine S, Oktaviani T. Profile And Risk Factors of Stevens Johnson Syndrome-Toxic Epidermal Necrolysis on Adult Patients in Dr.; 2024.
  • 14. Patel S, Shah R, Behbahani S, Lambert WC. Effect of diabetes mellitus on hospital complications of Stevens-Johnson syndrome and toxic epidermal necrolysis patients. J Am Acad Dermatol. 2019;81(4):196.
  • 15. Sharma C V., Mehta V. Paracetamol: Mechanisms and updates. Continuing Education in Anaesthesia, Critical Care and Pain. 2014;14(4):153-158. doi:10.1093/bjaceaccp/mkt049
  • 16. Kim EJ, Lim H, Park SY, Kim S, Yoon SY, Bae YJ, et al. Rapid onset of Stevens-Johnson syndrome and toxic epidermal necrolysis after ingestion of acetaminophen. Asia Pac Allergy. 2014;4(1):68-72. doi:10.5415/apallergy.2014.4.1.68
  • 17. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-245.
  • 18. Badan Pengawas Obat dan Makanan Republik Indonesia. Pedoman Monitoring Efek Samping Obat (MESO) Bagi Tenaga Kesehatan. Badan Pengawas Obat dan Makanan Republik Indonesia. Published online 2012:1-3. https://e-meso.pom.go.id/web/useruploads/files/reference/56275c6f02e91_PEDOMAN%20MESO_NAKES.pdf. Accessed December 8, 2023
  • 19. Badan Pengawas Obat dan Makanan Republik Indonesia. Buletin Berita MESO Monitoring Efek Samping Obat. Badan Pengawas Obat dan Makanan Republik Indonesia. 2023;41(1):1-3. https://e-meso.pom.go.id/web/useruploads/images/1230627043502--Buletin%20Berita%20MESO%20Edisi%20Juni%202023.pdf. Accessed September 25, 2023
  • 20. Uppsala Monitoring Centre. The use of the UMC system for standardised case causality assessment. Published April 6, 2018. https://who-umc.org/media/u4gjgxvv/who-umc-causality-assessment_new-logo.pdf. Accessed February 6, 2026
  • 21. Dewi CC. Tinjauan atas Stevens-Johnson Syndrome dan Toxic Epidermal Necrolysis. CDK Edisi Suplemen-2. 2019;46:55-59.
  • 22. Ueta M, Kaniwa N, Sotozono C, Tokunaga K, Saito Y, Sawai H, et al. Independent strong association of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe mucosal involvement. Sci Rep. 2014;4. doi:10.1038/srep04862
  • 23. Hotha PP, Naidu DM, Zachariah NE. Paracetamol is capable to cause Steven Johnson Syndrome: a case report. International Journal of Research in Pharmacology & Pharmacotherapeutics. 2020;9(1):37-40.
  • 24. Abdelli W, Chabchoub I, Rebhi F, Ben Slimane M, Youssef S, Jabeur K, et al. A Case Report Of Paracetamol-Induced Stenvens-Johnson Syndrome.; 2019. www.tcpdf.org
  • 25. Seminario-Vidal L, Kroshinsky D, Malachowski SJ, Sun J, Markova A, Beachkofsky TM, et al. Society of Dermatology Hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults. J Am Acad Dermatol. 2020;82(6):1553-1567. doi:10.1016/j.jaad.2020.02.066
  • 26. Chang HC, Wang TJ, Lin MH, Chen TJ. A Review of the Systemic Treatment of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis. Biomedicines. 2022;10(9). doi:10.3390/biomedicines10092105
  • 27. Andrew Isaac W, Fatimah N, Nurul Hidayati A. The Profiles of Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) Patients in Tertiary Hospital. Periodical of Dermatology and Venereolog. 2021;33(2):116-122.
  • 28. Ubukata N, Nakatani E, Hashizume H, Sasaki H, Miyachi Y. Risk factors and drugs that trigger the onset of Stevens–Johnson syndrome and toxic epidermal necrolysis: A population-based cohort study using the Shizuoka Kokuho database. JAAD Int. 2023;11:24-32. doi:10.1016/j.jdin.2022.12.002
  • 29. Witarini KA. Diagnosis dan tatalaksana Sindroma Stevens-Johnson (SJS) pada anak: tinjauan pustaka. Intisari Sains Medis. 2019;10(3). doi:10.15562/ism.v10i3.588
  • 30. Nagai K, Fukushima T, Oike H, Kobori M. High glucose increases the expression of proinflammatory cytokines and secretion of TNFα and β-hexosaminidase in human mast cells. Eur J Pharmacol. 2012;687(1-3):39-45. doi:10.1016/j.ejphar.2012.04.038
  • 31. Chandran K, Hink A, Kahn S, Ozhathil D. Outcomes for Patients with SJS/TENS with Diabetes Compared to other Comorbid Conditions. Journal of Burn Care & Research. 2023;44(2):583. https://academic.oup.com/jbcr/article/44/Supplement_2/S83/7162885
  • 32. Chandran K, Ozhathil D. Diabetes Mellitus Associated with Worse Outcomes in Stevens-Johnson Syndrome and Related Diseases. J Burn Care Res. 2023;44(2):162. https://academic.oup.com/jbcr/article/44/Supplement_2/S162/7162922
  • 33. Pandapotan RA, Rengganis I. Pendekatan Diagnosis dan Tata Laksana Alergi Obat Approach to Diagnosis and Treatment of Drug Allergy. Jurnal Penyakit Dalam Indonesia |. 2016;3(1).
There is no Supplemental content for this article.

How to Cite This

Febriola, N. T. F., Muzayyanah, B., Lilasari, S. P., Pratama, J. E., Setiadi , A. A. P., Herawati, F., & Gondokesumo, M. E. (2026). Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis Associated with Paracetamol in a Patient with Diabetes Mellitus. Jurnal Teknologi Laboratorium, 15(1), 87–95. https://doi.org/10.29238/teknolabjournal.v15i1.551

Article Metrics

Download Statistics

Downloads

Download data is not yet available.

Other Statistics

Verify authenticity via CrossMark

Copyright and Permissions

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Publishing your paper with Jurnal Teknologi Laboratorium (JTL) means that the author or authors retain the copyright in the paper. JTL granted an exclusive reuse license by the author(s), but the author(s) are able to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by JTL in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.

JTL journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially.

JTL journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:

  • BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • SA:  If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

Data Availability

All data generated during this study are included in this published article [and its supplementary information files].